IL2 and systemic sclerosis: Based on the elevated levels of IL-1 and IL-2 and their role in inflammation and fibrosis in SSc, the potential effect of the monoclonal antibodies rilonacept and basiliximab in tackling SSc-associated fibrosis has been examined lately.